Daniel V.T. Catenacci
University of Chicago(US)
Publications by Year
Research Areas
Gastric Cancer Management and Outcomes, Gastrointestinal Tumor Research and Treatment, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Esophageal Cancer Research and Treatment
Most-Cited Works
- → Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer(2018)1,796 cited
- → Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study(2020)1,533 cited
- → Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial(2016)1,123 cited
- → Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study(2020)1,025 cited
- → Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer(2019)622 cited
- → Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer(2015)532 cited
- → New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing(2014)460 cited
- → Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation(2021)450 cited
- → Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials(2021)424 cited
- → Biliary cancer: Utility of next‐generation sequencing for clinical management(2016)398 cited